View:
Download DOC
Download PDF
Download XLS

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-A

 

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

PURSUANT TO SECTION 12(b) OR (g) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Altimmune, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State of incorporation or organization)

  

20-2726770

(I.R.S. Employer Identification No.)

 

19 Firstfield Rd., Suite 200

Gaithersburg, MD

(Address of principal executive offices)

 

  

20878

(Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

 

Title of each class

to be so registered

  

 

Name of each exchange on which

each class is to be registered

Common Stock, par value $0.0001 per share   The Nasdaq Stock Market LLC

 

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. x

 

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. ¨

 

Securities Act registration statement file number to which this form relates:

 

(if applicable)

 

Securities to be registered pursuant to Section 12(g) of the Act:

 

None

(Title of class)

 

 

 

 

Item 1. Description of Registrant’s Securities to be Registered.

 

A description of the Registrant’s common stock, par value $0.0001 is set forth under the caption “Description of the Common Stock,” in the prospectus included in the Registrant’s Registration Statement on Form S-3 (Registration No. 333-217034), filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2017 under the Securities Act of 1933, and will be set forth in any prospectus filed in accordance with Rule 424(b) thereunder, which description is incorporated herein by reference.

 

Item 2. Exhibits.

 

In accordance with the “Instructions as to Exhibits” with respect to Form 8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

 

Dated: May 4, 2017

 

  Altimmune, Inc.
 

 

By:

 

/s/ William Enright

    William Enright
    Chief Executive Officer